Capstone Therapeutics Corp. (CAPS)
(Delayed Data from NSDQ)
$1.18 USD
-0.17 (-12.59%)
Updated Oct 15, 2025 04:00 PM ET
After-Market: $1.18 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CAPS 1.18 -0.17(-12.59%)
Will CAPS be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CAPS based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for CAPS
Crossed Above 20 Day Moving Average appears for CAPS after 20.54% move
12 Industrials Stocks Moving In Wednesday's Pre-Market Session
Is CAPS primed for volatility? NR7 shows up after dropping 0.88%
Capstone Holding (CAPS) Achieves Early Success Post-Carolina Stone Integration
Capstone Therapeutics achieves milestones in Carolina Stone integration